NCT01694472Unknown1 期
Phase 1 Study of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors
Tianjin Medical University Cancer Institute and Hospital1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2012年7月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Objective response rate
研究概览
简要总结
The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MAGE-A4 TCR Gene-Modified T lymphocytes in the treatment of malignant solid tumor patients, such as malignant melanoma and lung cancer.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Supportive Care
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Sex: male or female
- •Age: from 18 to 80 years
- •Patients must have histologically confirmed solid tumors that have failed standard therapies (surgery, chemotherapy, radiotherapy) and for which no curative options exist, including, but not limited to:
- •Non-Small Cell Lung Carcinoma Malignant melanoma Esophageal carcinoma Head and neck carcinoma
- •HLA-A*24:02
- •MAGE-A4 positive in the test by RT-PCR on tumor tissue or immunohistochemistry of resected tissue of the patient.
- •PS ECOG 0 or <2
- •Laboratory tests results 7 days before the start of treatment:
- •White blood cells: more than 3.0 × 109/L Platelets: more than 100 × 109/L Neutrophils: more than 1.5 × 109/L Hemoglobin: more than 80g/L Serum glutamate pyruvate transaminase: less than 2.5 folds of the upper normal limit (ULN) Serum glutamic-oxal (o) acetic transaminase: less than 2.5 × ULN Serum bilirubin: less than 1.25 × ULN Serum creatinine: less than 1.25 × ULN
- •Pregnancy test: the test of women of child-bearing period must be negative 7 days before the start of treatment
- •Contraception: male and female subjects of child-bearing period must adopt a reliable method of contraception before entry into this study until 30 days after stopping this study
- •Informed consent: subject must have the ability to understand and voluntarily sign a written informed consent
排除标准
- •Patients with life-threatening condition or complication other than their basic disease
- •Pregnant or lactation. Patients both males and female with reproductive potential (i.e. menopausal for less than 1 year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of childbearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration
- •Active systemic infections
- •History of neoplasms: other neoplasms
- •Medical history: active CNS disease, or congestive heart failure, or severe coronary artery disease, or cardiac arrhythmias, or concomitant corticosteroid therapy
- •Metastasis: clinical symptoms of brain metastasis
- •Other clinical trial: the subject received other clinical trial before this study
- •Laboratory tests: the serum test of human immunodeficiency virus, or hepatitis B virus, or hepatitis C virus was positive
- •Compliance: poor compliance
研究组 & 干预措施
MAGE-A4 TCR Gene-Modified T Cells
Experimental
干预措施: MAGE-A4 TCR Gene-Modified T Cells (Biological)
结局指标
主要结局
Objective response rate
时间窗: Up to 12 months
CR + PR = ORR
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
招募中
早期 1 期
Genetically Modified T Cells Treating Malignant TumorsSolid TumorNCT06515626Yi Zhang100
进行中（未招募）
1 期
MAGE-A4ᶜ¹º³²T for Multi-TumorUrinary Bladder CancerGastroesophageal JunctionSynovial SarcomaMyxoid Round Cell LiposarcomaHead and Neck CancerOvarian CancerGastric CancerMelanomaEsophageal CancerNon-Small Cell Lung CancerNCT03132922USWM CT, LLC71
进行中（未招募）
1 期
A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasRecurrent B-Cell Non-Hodgkin LymphomaRecurrent Transformed Chronic Lymphocytic LeukemiaRecurrent Chronic Lymphocytic LeukemiaRecurrent Diffuse Large B-Cell LymphomaRecurrent Follicular LymphomaRefractory B-Cell Non-Hodgkin LymphomaRecurrent Lymphoplasmacytic LymphomaRecurrent Mantle Cell LymphomaRecurrent Marginal Zone LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Follicular LymphomaRefractory Mantle Cell LymphomaRefractory Lymphoplasmacytic LymphomaRefractory Transformed Non-Hodgkin LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Marginal Zone LymphomaRefractory Transformed B-Cell Non-Hodgkin LymphomaRefractory Transformed Chronic Lymphocytic LeukemiaRecurrent Central Nervous System LymphomaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic LeukemiaRefractory Small Lymphocytic LymphomaRefractory Central Nervous System LymphomaNCT03277729Fred Hutchinson Cancer Center53
尚未招募
1 期
Safety and Efficacy Evaluation of 4th Generation Safety-engineered CAR T Cells Targeting SarcomasSarcomaEwing SarcomaOsteoid SarcomaNCT03356782Shenzhen Geno-Immune Medical Institute20
进行中（未招募）
1 期
Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell NeoplasmAdult Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaMinimal Residual DiseaseAdult Acute Myeloid Leukemia in RemissionRecurrent Adult Acute Myeloid LeukemiaBlastic Plasmacytoid Dendritic Cell NeoplasmInterleukin-3 Receptor Subunit Alpha PositiveAcute Biphenotypic LeukemiaLate Relapse of Acute Myeloid LeukemiaSecondary Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaEarly Relapse of Acute Myeloid LeukemiaUntreated Adult Acute Myeloid LeukemiaNCT02159495City of Hope Medical Center31